SAN DIEGO , Oct. 26 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that the Company will present at three upcoming investor conferences:

    (Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

    -- Richard Ghalie, M.D., Chief Medical Officer, will present at the BIOCOM
       Investor Conference at 11:00 a.m. Pacific time on Friday, November 2,
       2007, from the San Diego Marriott Del Mar;
    -- John P. Longenecker, Ph.D., President and Chief Executive Officer, will
       present at the Acumen BioFin Rodman & Renshaw Healthcare Conference at
       10:35 a.m. Eastern time on Monday, November 5, 2007, from the New York
       Palace Hotel; and
    -- Dr. Longenecker will also present at the CIBC World Markets Healthcare
       Conference at 1:20 p.m. Eastern time on Monday, November 5, 2007, from
       the Waldorf-Astoria in New York.

Live webcasts of all three presentations can be accessed at http://www.favrille.com. Replays will be available approximately one hour after each presentation and archived for one month.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

SOURCE Favrille, Inc.